Results 171 to 180 of about 427,163 (354)

Development of New Benzo[b]Thiophene‐2‐Carboxamide Derivatives as Advanced Glycation End‐Products Receptor (RAGE) Antagonists

open access: yesChemMedChem, EarlyView.
A streamlined Ullmann‐Goldberg strategy enabled the synthesis of benzo[b]thiophene‐2‐carboxamides, promising ligands of the pro‐inflammatory RAGE receptor involved in inflammaging and age‐related diseases. LC‐MS, NMR, X‐ray and DFT studies elucidated the copper‐catalyzed mechanism. The lead compound, 3t’, shows inhibitory activity on the sRAGE/AGE2‐BSA
Lisa Bonin   +10 more
wiley   +1 more source

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

open access: yesNew England Journal of Medicine, 2007
D. Black   +20 more
semanticscholar   +1 more source

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali   +4 more
wiley   +1 more source

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

open access: yesNew England Journal of Medicine, 2017
K. Saag   +9 more
semanticscholar   +1 more source

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy